DK1808164T3 - Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol - Google Patents

Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol

Info

Publication number
DK1808164T3
DK1808164T3 DK06251324T DK06251324T DK1808164T3 DK 1808164 T3 DK1808164 T3 DK 1808164T3 DK 06251324 T DK06251324 T DK 06251324T DK 06251324 T DK06251324 T DK 06251324T DK 1808164 T3 DK1808164 T3 DK 1808164T3
Authority
DK
Denmark
Prior art keywords
aripiprazole
pharmaceutical compositions
wet granulation
granulation method
preparing pharmaceutical
Prior art date
Application number
DK06251324T
Other languages
Danish (da)
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36637023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1808164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1808164T3 publication Critical patent/DK1808164T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06251324T 2006-01-05 2006-03-14 Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol DK1808164T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75670806P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
DK1808164T3 true DK1808164T3 (da) 2009-04-20

Family

ID=36637023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06251324T DK1808164T3 (da) 2006-01-05 2006-03-14 Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol

Country Status (13)

Country Link
US (1) US8865722B2 (es)
EP (2) EP1808164B2 (es)
JP (1) JP4875001B2 (es)
CN (1) CN101351192A (es)
AT (1) ATE419837T1 (es)
CA (1) CA2627693A1 (es)
DE (1) DE602006004694D1 (es)
DK (1) DK1808164T3 (es)
ES (1) ES2318693T5 (es)
IL (1) IL190916A0 (es)
PL (1) PL1808164T3 (es)
PT (1) PT1808164E (es)
WO (1) WO2007081366A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
US20120214820A1 (en) 2009-09-15 2012-08-23 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102106826B (zh) * 2009-12-29 2013-06-05 上海中西制药有限公司 一种阿立哌唑固体制剂及其制备方法
PT2563763E (pt) * 2010-04-30 2015-03-31 Bristol Myers Squibb Co Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
ES2589460T3 (es) * 2011-12-08 2016-11-14 Hexal Ag Nueva composición farmacéutica de estatina
WO2013100878A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical formulations comprising aripiprazole
WO2014104989A1 (en) * 2011-12-27 2014-07-03 Mahmut Bilgic Pharmaceutical compositions comprising aripiprazole
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
CN105246461B (zh) * 2013-04-30 2018-03-30 大塚制药株式会社 包含阿立哌唑的口服固体制剂以及用于产生包含阿立哌唑的口服固体制剂的方法
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
GR1008442B (el) * 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EP3002005A1 (en) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71629C2 (en) 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI324074B (en) 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1606262A1 (en) 2003-03-21 2005-12-21 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20060270683A1 (en) 2003-04-25 2006-11-30 Lohray Braj B Polymorphs of aripiprazole
CN101005829A (zh) 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
WO2005058835A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
WO2005067976A2 (en) 2004-01-20 2005-07-28 Novartis Ag Direct compression formulation and process
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006053780A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
WO2006053781A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
EP1686117A1 (en) 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole
EP2783688A1 (en) 2005-03-17 2014-10-01 Synhton B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
CA2605128A1 (en) 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
US20070014853A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
CA2614468A1 (en) 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
JP2008537540A (ja) 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
CA2626234A1 (en) 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2007092779A2 (en) 2006-02-03 2007-08-16 Dr. Reddy's Laboratories Ltd. Aripiprazole co-crystals
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof

Also Published As

Publication number Publication date
EP1808164B1 (en) 2009-01-07
EP1808164A1 (en) 2007-07-18
ES2318693T3 (es) 2009-05-01
CN101351192A (zh) 2009-01-21
CA2627693A1 (en) 2007-07-19
US20070154544A1 (en) 2007-07-05
WO2007081366A1 (en) 2007-07-19
DE602006004694D1 (de) 2009-02-26
PT1808164E (pt) 2009-03-17
PL1808164T3 (pl) 2009-06-30
IL190916A0 (en) 2008-11-03
ATE419837T1 (de) 2009-01-15
ES2318693T5 (es) 2018-10-04
US8865722B2 (en) 2014-10-21
EP2036545A1 (en) 2009-03-18
JP4875001B2 (ja) 2012-02-15
EP1808164B2 (en) 2018-07-04
JP2008531737A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
DK1808164T3 (da) Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
NL1030863A1 (nl) Heteroaromatische chinolineverbindingen.
DK1808165T3 (da) Törre formuleringer af aripiprazol
BRPI0810646A2 (pt) " compostos farmacêuticos ".
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
DK2041139T3 (da) Farmaceutiske forbindelser
NL2000480A1 (nl) Nieuwe farmaceutische middelen.
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
DK2049487T3 (da) Fremgangsmåde til fremstilling af 2-substituerede 5-(1-alkylthio)alkylpyridiner
CR10353A (es) Nuevos compuestos.
ITMI20071002A1 (it) Manufatto per edilizia.
DK2061746T3 (da) Fremgangsmåde til fremstilling af diestere
BRPI0720234A2 (pt) Composição farmacêutica
DK2093217T3 (da) Fremgangsmåde til fremstilling af form X af aripiprazol
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
BRPI0812234A2 (pt) Composto de quinolona e composição farmacêutica.
FR2923834B1 (fr) Nouvelles compositions polysicocyanates hydrodispersibles.
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK1994138T3 (da) Fremgangsmåde til fremstilling af humant g-csf
BRPI0807853A2 (pt) Prendedor para vestuário.
DK1857120T3 (da) Infusion til mastitis